BioSenic SA is a biotechnology company specializing in regenerative and immune medicine, developing innovative products for inflammatory diseases, bone disorders, and related medical devices. Formed through the 2022 merger of Medsenic and Bone Therapeutics, it leverages the arsenic trioxide (ATO) platform to create anti-inflammatory and anti-autoimmune formulations, including oral ATO (OATO), targeting conditions such as graft-versus-host disease (GvHD), systemic lupus erythematosus (SLE), and systemic sclerosis (SSc). The company also advances orthopedics and regenerative therapies, with historical focus on cell therapies for bone regeneration, osteonecrosis, fractures, and osteoarthritis, though it has shifted away from direct development of certain assets like JTA-004 and ALLOB. Currently, BioSenic co-develops 4P004v with 4Moving Biotech, a veterinary GLP-1 analog for post-surgical ligament repair in dogs, addressing a key unmet need in veterinary orthopedics. Headquartered in Belgium with a small team of two employees, BioSenic emphasizes clinical assets for high-value indications, collaborative innovation, and accelerated market paths in the pharmaceuticals sector.